Key result
High circulating ANGPTL2 levels were associated with an increased risk of all-cause mortality in patients receiving maintenance hemodialysis.
Why the study?
Patients receiving hemodialysis have a poor prognosis often driven by premature aging phenotypes and systemic inflammation, but whether ANGPTL2 is associated with increased mortality risk in this population was unknown.
Are circulating ANGPTL2 levels associated with increased mortality risk in patients receiving maintenance hemodialysis?
Cohort (n=412)
Yes
Are circulating ANGPTL2 levels associated with increased mortality risk in patients receiving maintenance hemodialysis?
Circulating ANGPTL2 levels are positively associated with mortality risk in patients receiving maintenance hemodialysis, potentially serving as a marker for premature aging and subsequent mortality.
Answers are grounded in this paper and cite their sources.
May aid risk stratification in hemodialysis; hypothesis-generating and requires prospective validation before any clinical use.
BACKGROUND: Patients undergoing hemodialysis treatment have a poor prognosis, as many develop premature aging. Systemic inflammatory conditions often underlie premature aging phenotypes in uremic patients. We investigated whether angiopoietin-like protein 2 (ANGPTL 2), a factor that accelerates the progression of aging-related and noninfectious inflammatory diseases, was associated with increased mortality risk in hemodialysis patients. METHODS: We conducted a multicenter prospective cohort study of 412 patients receiving maintenance hemodialysis and evaluated the relationship between circulating ANGPTL2 levels and the risk for all-cause mortality. Circulating ANGPTL2 levels were log-transformed to correct for skewed distribution and analyzed as a continuous variable. RESULTS: Of 412 patients, 395 were included for statistical analysis. Time-to-event data analysis showed high circulating ANGPTL2 levels were associated with an increased risk for all-cause mortality after adjustment for age, sex, hemodialysis vintage, nutritional status, metabolic parameters and circulating high-sensitivity C-reactive protein levels {hazard ratio [HR] 2.04 [95% confidence interval (CI) 1.10-3.77]}. High circulating ANGPTL2 levels were also strongly associated with an increased mortality risk, particularly in patients with a relatively benign prognostic profile [HR 3.06 (95% CI 1.86-5.03)]. Furthermore, the relationship between circulating ANGPTL2 levels and mortality risk was particularly strong in patients showing few aging-related phenotypes, such as younger patients [HR 7.99 (95% CI 3.55-18.01)], patients with a short hemodialysis vintage [HR 3.99 (95% CI 2.85-5.58)] and nondiabetic patients [HR 5.15 (95% CI 3.19-8.32)]. CONCLUSION: We conclude that circulating ANGPTL2 levels are positively associated with mortality risk in patients receiving maintenance hemodialysis and that ANGPTL2 could be a unique marker for the progression of premature aging and subsequent mortality risk in uremic patients, except those with significant aging-related phenotypes.
No takes yet. Share an insight, caveat, or question.
Morinaga et al. (2019) conducted a cohort in Maintenance hemodialysis (n=412). High circulating ANGPTL2 levels was evaluated on All-cause mortality (HR 2.04, 95% CI 1.10-3.77). High circulating ANGPTL2 levels were associated with an increased risk of all-cause mortality in patients receiving maintenance hemodialysis.
Synapse has enriched 10 related papers. Consider them for comparative context: